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Abstract
Background: Randomised controlled trials (RCTs) are considered the gold standard form of evidence for assessing
treatment efficacy, but many factors can influence their reliability including methodological quality, reporting
quality and funding source.
The aim of this study was to examine the relationship between funding source and positive outcome reporting in
veterinary RCTs published in 2011 and to assess the risk of bias in the RCTs identified.
Methods: A structured search of PubMed was used to identify feline, canine, equine, bovine and ovine clinical trials
examining the efficacy of pharmaceutical interventions published in 2011. Funding source and outcomes were
extracted from each RCT and an assessment of risk of bias made using the Cochrane risk of bias tool.
Results: Literature searches returned 972 papers, with 86 papers (comprising 126 individual RCTs) included in the
analysis. There was found to be a significantly higher proportion of positive outcomes reported in the
pharmaceutical funding group (P) compared to the non-pharmaceutical (NP) and ‘no funding source stated’ (NF)
groups (P = 56.9%, NP = 34.9%, NF = 29.1%, p < 0.05). A high proportion of trials had an unclear risk of bias across
the five criteria examined.
Conclusions: We found evidence that veterinary RCTs were more likely to report positive outcomes if they have
pharmaceutical industry funding or involvement. Consistently poor reporting of trials, including non-identification of
funding source, was found which hinders the use of the available evidence.
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Background
In order to effectively practice veterinary medicine in an
evidence-based way, it is imperative that accurate scien-
tific evidence is available so that the evidence base is
complete, reliable, and therefore not misleading. Rando-
mised controlled trials (RCTs), along with their synthesis
in the form of systematic reviews, are considered to be the
gold standard method for assessing the efficacy of treat-
ment interventions and are a valuable source of informa-
tion on which to base clinical decisions [1]. The results of
RCTs can however be affected by many biases including
selection, performance, detection, attrition and reporting
biases [2, 3]. The presence of bias can lead to misinter-
pretation of treatment efficacy or harms, and mislead
clinicians when putting the evidence into practice.
Sponsorship bias (the influence of funding source on
the reporting of trial results) is an additional potential
problem when assessing the reliability of RCTs. The
medical literature contains differing reports over whether
financial conflicts of interest influence the reported results
of a trial. Some studies report a greater likelihood of
positive results for industry funded trials [4, 5], while some
report no difference between industry and non-industry
sponsored trials [6, 7]. A recent overview of medical
literature in a Cochrane systematic review concluded that
drug and medical device studies were more likely to report
favourable results when the study was sponsored by a
manufacturer [8].
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There have been several studies examining the methodo-
logical and reporting quality of clinical trials in the pub-
lished veterinary literature [9–11]. Such studies have
highlighted issues with the reporting of RCTs and have
shown how these reporting deficiencies are associated with
an increased likelihood of a trial reporting one or more
positive outcomes [10]. To our knowledge, no studies to
date have examined the influence of funding source on the
likelihood of reporting positive outcomes in the veterinary
RCT literature.
The aim of this study was to examine the relationship
between funding source and proportions of positive out-
come reporting in veterinary RCTs involving a pharmaceut-
ical intervention published in a single calendar year (2011).
A secondary aim was to assess the risk of bias of veterinary
RCTs published in the same time period.
Methods
A cross-sectional study of veterinary RCTs was conducted.
The target population was feline, canine, equine, bovine
and ovine RCTs where a pharmaceutical agent was the
intervention of interest and efficacy was assessed. The
sample population was feline, canine, equine, bovine and
ovine RCTs published in 2011 within journals indexed in
PubMed.
Search strategy and filtering of results
A structured search of PubMed was conducted in June
2013 using the “clinical trial” Publication Type combined
with the relevant species MeSH heading e.g. “clinical trial”
[publication type] AND cats [mh]. This was done for each
of the 5 species studied: cats, dogs, horses, cattle and
sheep (Fig. 1). The search was limited to one calendar year
with a PubMed filter: 01/01/11–31/12/11. Search results
were exported into EndNote® software for filtering. Papers
indexed as RCTs by PubMed (“randomised controlled tri-
als” [publication type]) were extracted, investigators then
confirmed if they were RCTs according to the Cochrane
definition below (http://www.cochrane.org/glossary/):
“An experiment in which two or more interventions,
possibly including a control intervention or no interven-
tion, are compared by being randomly allocated to partici-
pants. In most trials one intervention is assigned to each
individual but sometimes assignment is to defined groups
of individuals (for example, in a household) or interven-
tions are assigned within individuals (for example, in dif-
ferent orders or to different parts of the body).”All
publications containing trials confirmed by the investiga-
tors as being RCTs, published in 2011, and relevant to the
species of interest were then categorised into four inter-
vention subcategories based on the main intervention of
interest of the study (Table 1 - Level 1 exclusion criteria):
1. Pharmaceutical – consisting of an active
pharmaceutical ingredient, including anthelmintics
and vaccines
2. Nutritional
3. Para-pharmaceutical – including probiotics,
prebiotics, synbiotics, nutraceuticals and
supplements/vitamins/minerals if not considered
part of the total dietary ration
4. Other – including surgical interventions,
management/husbandry interventions, non-
medicinal shampoos, studies relating to diagnostic
tests.
Only publications within the ‘Pharmaceutical interven-
tion’ subcategory were included in this study; these were
assessed for further eligibility for analysis according to
the second level of inclusion and exclusion criteria in
Table 1.
Publications included in the analysis were therefore
single dose efficacy studies of pharmaceutical inter-
ventions in cats, dogs, horses, cattle or sheep pub-
lished in 2011. In the case of a publication containing
more than one trial, each trial was included inde-
pendently in the analysis if it met all inclusion
criteria.
Sources of funding
For each included trial the source of funding was categorised
as one of the following:
1. Pharmaceutical company funding stated or
pharmaceutical company involvement (e.g. drug
donated by a pharmaceutical company or authors
associated with a pharmaceutical company) (P)
2. Non-pharmaceutical company funding stated (NP)
3. No funding source stated (NF)
Outcome recording
All outcomes mentioned in the methods section of the
manuscripts were extracted and the result for each out-
come was recorded. Outcomes that were reported as re-
sults but not mentioned in the methods were not
included in the analysis. The result for each outcome
was recorded in one of the five categories below
(adapted from [10]):
1. Treatment of interest had a statistically significant
positive effect on the outcome
▪ Treatment better than any control group
▪ Treatment equal to positive control group
(whether non-inferiority/equivalence design
or not)
▪ Safety/lack of adverse effects equal to, or better
than, any control group
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2. Treatment of interest had a statistically significant
negative effect on the outcome
▪ Treatment worse than any control group
▪ Treatment equal to negative control group
▪ Safety/adverse effects worse than any control group
▪ Treatment equal to a positive control group in a
superiority analysis
3. No significant difference between treatment and
control groups
▪ Outcome remained constant throughout the study
(no measurable effect of treatment on the outcome)
4. Results for the outcome were described only
▪ There was data reported for an outcome that could
have been statistically analysed, but no analysis was
presented (if an outcome did not occur in any
group, e.g. adverse events, it was treated as having
been statistically analysed)
▪ Outcomes such as descriptions of pathological
appearances with no numerical data attached.
5. Results for the outcome were not reported
Outcome measures that had multiple components (e.g.
complete blood count and serum biochemistry, meat yield
and meat quality grade assessments) were classed as a sin-
gle outcome each unless specific features were relevant to
Fig. 1 Summary of the number of papers retrieved from literature searches, numbers of papers excluded using Level 1 and 2 exclusion criteria
and number of papers and individual trials analysed for each species and overall
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the disease, in which case these were extracted as individual
outcomes. If an outcome had a result recorded at multiple
time points, an overall judgement was made as to which of
the above categories was most appropriate (i.e. the outcome
was only recorded once regardless of how many time
points it was measured). Where multiple treatment and
control groups were used, each group containing the treat-
ment of interest (either alone or in combination) was com-
pared to its relevant control group for each outcome.
Risk of bias assessment
All the included studies were assessed at the study level
using the Cochrane risk of bias tool [2]. The five features
assessed were: random sequence generation, allocation con-
cealment, blinding, incomplete outcome data and selective
outcome reporting. Following the Cochrane guidelines for
the risk of bias tool each category was assessed as being at
a high, low or unclear risk of bias. These features allow the
risks of selection bias, performance bias, detection bias,
attrition bias and reporting bias to be assessed (see
Additional file 1 for definitions of these types of bias). We
did not include the category of ‘Other bias’ from the tool.
All assessments made throughout the study were
agreed upon by two authors (KW and RH/RD) with any
disputes resolved by a third author (RD/RH).
Statistical analysis
Categorical data were presented descriptively as raw num-
bers and percentages. Associations between funding source
and positive outcome reporting were analysed using a
Pearson’s chi squared test and Bonferroni post hoc test with
adjusted p values. Significance level was set at p < 0.05.
Results for different species are described only and were
not compared statistically due to small group sizes. All stat-
istical analyses were conducted in IBM SPSS Version 21.
Results
Overall study numbers
A total of 972 papers were retrieved from the initial
searches (96 for cats, 255 for dogs, 135 for horses, 371 for
cattle and 115 for sheep; Fig. 1). Following an initial review
and exclusions based on year of publication in paper copy
and species of interest there were 410 papers given the
Publication Type for RCTs in PubMed; 390 of which were
confirmed to be RCTs according to the Cochrane
definition. Of these, 172 papers (172/390, 44.1%) were
describing RCTs in which the treatment of interest was a
pharmaceutical intervention and were included in further
analysis (Fig. 1). The remainder comprised nutritional
studies (121/390, 31.0%), para-pharmaceutical agent stud-
ies (17/390, 4.4%) and ‘other RCTs’ (80/390, 20.5%).
Following application of the second set of exclusion cri-
teria to the RCT pharmaceutical intervention studies, 86
papers remained in the study from which outcomes, bias
and sources of funding were extracted (Fig. 1, Table 2 and
Additional file 2: Table S1). Eleven papers (all except one
of which were within the pharmaceutical funding group)
reported more than one RCT, notably one sheep paper re-
ported 19 separate RCTs. As each trial was assessed indi-
vidually as a separate entry, there were 126 trials included
in the full analysis (Table 2 and Additional file 3 for full
references of the publications analysed).
Of these 126 trials, 86 (68.3%) were funded by the
pharmaceutical industry or had pharmaceutical company
involvement, 19 trials (15.1%) explicitly stated they were
not funded by the pharmaceutical industry, and 21 trials
(16.7%) did not state any source of funding within the
manuscript (Table 2).
Funding source and outcome reporting
From the 126 trials included in the analysis, a total of 960
outcomes were extracted. Overall, 47.5% of outcomes
(456/960) recorded in the trials were statistically positive
Table 1 Two levels of inclusion and exclusion criteria applied to the search results
Level 1: Inclusion criteria for publications Level 1: Exclusion criteria for publications
Species of interest is cats, dogs, horses, cattle or sheep Not about cats, dogs, horses, cattle or sheep
Published in 2011 E published only in 2011 if full publication occurred in a different calendar year
RCT according to PubMed publication types and the
Cochrane definition
Not an RCT (not indexed as an RCT by PubMed or not fulfilling
Cochrane definition of an RCT)
Treatment of interest is a pharmaceutical intervention
(including anthelmintics and vaccines)
Treatment of interest is not a pharmaceutical agent e.g. nutritional,
surgical, animal husbandry etc
Level 2: Inclusion criteria for analysis of pharmaceutical RCTs Level 2: Exclusion criteria for analysis of pharmaceutical RCTs
Primary aim is to assess efficacy Primary aim was not to assess efficacy (pharmacokinetic/dynamic studies,
safety studies, physiological effects, resistance testing, testing routes of
administration only, testing timing of administration only)
Identifiable treatment or protocol of interest Treatment or protocol of interest could not be identified
Single dose of the treatment of interest used Multiple doses of the treatment of interest used/dose finding studies
Published in English Not available in English
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compared to 28.8% (276/960) which were recorded as
being statistically negative; 1.9% of outcomes (18/960)
remained unchanged during the study (no significant
difference category), 14.7% of outcomes (141/960) were
described only and 7.2% (69/960) were not reported at all
in the results (Table 3).
Between funding groups there were significant differ-
ences in the proportions of outcomes recorded in each of
the outcome categories (Table 3, Pearsons chi squared,
p < 0.001). The proportion of positive outcomes reported
was significantly higher in the pharmaceutical group than
in the non-pharmaceutical and ‘no funding source stated’
groups (P = 56.9%, NP = 34.9%, NF = 29.1%, p < 0.05).
Correspondingly, there was a significantly lower propor-
tion of negative outcomes recorded for the pharmaceutical
group compared to the other two groups (P = 23.5%,
NP = 37.6%, NF = 37.1%, p < 0.05). Across all funding
groups the proportion of outcomes recorded as ‘no signifi-
cant difference’ was low, however the ‘no funding group’
had a significantly higher proportion compared to the
pharmaceutical group (NF = 4.6%, P = 0.8%, p < 0.05); the
non-pharmaceutical group was not different to either of
the other two groups (NP = 2.6%, p > 0.05). There were
no significant differences between the funding groups in
the proportion of ‘described only’ or ‘not reported’ out-
comes (p > 0.05).
The above analysis categorised a treatment group which
had equal results to a positive control group as a ‘positive’
outcome, even if the study did not use a non-inferiority
design. If these results were instead considered to be in a
‘no significant difference’ category, the pattern of signifi-
cantly higher positive, and lower negative, outcome
reporting in the pharmaceutical group compared to the
other two groups was still present (p < 0.05).
Risk of bias assessment
Of the 126 included trials, the majority (92/126, 73.0%)
were assessed as having an unclear risk of selection bias as
there was inadequate or no description of how randomisa-
tion sequences were generated and employed. The vast
majority of the trials were assessed as having an unclear
risk of bias for allocation concealment (109/126, 86.5%) as
it was impossible to determine what procedures had been
followed. Blinding was reported more consistently, with
44 of the 126 trials (34.9%) being assessed as having a low
risk of bias, 72/126 (57.1%) having an unclear risk, and the
Table 2 Number and funding source of papers and individual trials following level 2 exclusion criteria application
Number of cat
papers (trials)
Number of dog
papers (trials)
Number of horse
papers (trials)
Number of cattle
papers (trials)
Number of sheep
papers (trials)
Total number of papers
(trials, % of total trials)
Papers including pharmaceutical
agent RCTs
17 49 28 61 17 172
Papers excluded from analysisa 9 21 17 29 10 86
Papers analysed 8 (9 trials) 28 (44 trials) 11 (11 trials) 32 (36 trials) 7 (26 trials) 86 (126 trials)
Funding sources of analysed
papers
Pharmaceutical company funded/
pharmaceutical company
involvement
4 (5 trials) 17 (33 trials) 4 (4 trials) 20 (23 trials) 2 (21 trials) 47 (86 trials; 68.3%)
Non pharmaceutical funding
stated
3 (3 trials) 4 (4 trials) 2 (2 trials) 6 (7 trials) 3 (3 trials) 18 (19 trials; 15.1%)
No funding stated 1 (1 trial) 7 (7 trials) 5 (5 trials) 6 (6 trials) 2 (2 trials) 21 (21 trials; 16.7%)
Included studies are the pharmaceutical agent RCTs. aSee Additional Table 1 for reasons for exclusions from analysis. There was no statistical difference (p = 0.53)
between funding sources between companion animal species (cats, dogs and horses) and farm animal species (cows and sheep)
Table 3 Categorisation of individual outcomes from 126 trials (960 outcomes)
Outcomes from trials with
pharmaceutical funding/involvement
Outcomes from trials with
non-pharmaceutical funding stated
Outcomes from trials with no
funding source stated
Outcomes from
all trials
Positive outcomes 56.9% (339/596)a 34.9% (66/189)b 29.1% (51/175)b 47.5% (456/960)
Negative outcomes 23.5% (140/596)a 37.6% (71/189)b 37.1% (65/175)b 28.8% (276/960)
No difference 0.8% (5/596)a 2.6% (5/189)a,b 4.6% (8/175)b 1.9% (18/960)
Described only 12.8% (76/596) 16.9% (32/189) 18.9% (33/175) 14.7% (141/960)
Not reported 6.0% (36/596)s 7.9% (15/189) 10.3% (18/175) 7.2% (69/960)
Data shown as percentages and raw numbers in brackets. Significant differences (p < 0.05) existing between funding categories within rows are indicated by
differing subscript letters. (No subscript letters in a row signifiy no significant differences. The presence of a subscript letter (e.g. ‘a’ in a cell indicates that it is
significantly different from a cell marked with a different letter (e.g. ‘b’). If a cell has two subscript letters (e.g. ‘a,b’) then it is different from cells individually
marked with each letter)
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remaining 10 (7.9%) having a high risk of bias. Around
half of the trials (65/126, 51.6%) were at low risk of bias
for incomplete outcome reporting. There was a high risk
of bias for incomplete outcome reporting in 19 out of the
126 trials (15.1%) due to missing data, or lack of analysis
of the full population of animals randomised in the trial.
Twenty-nine of the 126 trials (23.0%) were judged to be at
a high risk of bias for selective outcome reporting, only
10/126 (7.9%) were at an unclear risk of bias, and the
remaining 87 (69.0%) were assessed as being at a low risk
of bias (Fig. 2 and Table 4).
The results of comparing the quality criteria across the
trials in different funding are shown in Table 4. The
highest percentage of unclear risk for sequence gener-
ation was in the pharmaceutical group where 67 out of
86 trials (77.9%) were judged to be at an unclear risk of
bias with a lower proportion in the non-pharmaceutical
group (12/19, 63.2%) and 3/21 (61.9%) in the no funding
declared group (13/21, 61.9%). The pharmaceutical
group also had a higher proportion of unclear risk for
incomplete outcome reporting in comparison to the
other two funding groups (P = 36/86, 41.9%, NP = 3/19,
15.8%, NF = 3/21, 14.3%) and a correspondingly lower
proportion of trials in the low risk category for this cri-
teria. The high risk for selective outcome reporting was
seen across all the funding categories (P = 18/86, 20.9%;
NP = 5/19, 26.3%; NF = 6/21, 28.6%), however the
pharmaceutical group had the largest proportion of
studies in the low risk category for this criteria com-
pared to the other groups (P = 64/86, 74.4%, NP = 11/
19, 57.9%, NF = 12/21, 57.1%). Similar distributions of
risk for blinding and allocation concealment were seen
across the funding groups (Table 4).
Discussion
This study found a significantly higher proportion of posi-
tive outcomes reported in RCTs with pharmaceutical
funding (56.9%) or involvement compared to those with
declared non-pharmaceutical funding (34.9%) or with no
funding source stated (29.1%) within the sample of litera-
ture studied. There was a correspondingly lower propor-
tion of negative outcomes reported in trials within the
pharmaceutical funding group (23.5%) compared to the
other two groups (37.6% and 37.1%). When assessing the
trials for risk of bias across the five main categories using
the Cochrane risk of bias tool, a large proportion were at
an ‘unclear’ risk indicating significant reporting deficien-
cies. A high risk of bias was most predominantly seen for
selective outcome reporting (reporting bias), and more
moderately for incomplete outcome data (attrition bias)
and blinding (detection bias). Proportions of trials at high,
low or unclear risk of bias for the different quality criteria
were largely similar across funding categories.
The sponsorship bias detected in this study is in accord-
ance with many reports in the medical literature where an
association between funding source and positive results
has been demonstrated, most notably in a Cochrane
Review of drug and medical devices [8]. There are many
reasons why such a bias may be present in the published
literature including differences in the methodological
quality of trials; inherent biases in trial conduct to favour
a treatment; a genuinely greater likelihood that pharma-
ceutical companies would be testing pharmaceutical
agents that are likely to perform well; and inadequacies in
trial reporting which favour a treatment. Additionally,
publication bias may play a role through researchers
within different environments potentially being more or
Fig. 2 Percentages of all trials (N = 126) at high, low or unclear risk of bias for the five criteria assessed
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less likely to publish trials demonstrating a positive effect
compared to trials showing a ‘negative’ result. Further
studies are required to examine this finding and its poten-
tial causative factors in more detail, in particular whether
there are correlations between quality criteria and funding
source, something which this study did not investigate.
There are a variety of methods that could have been uti-
lised for the current study. For example, in medical litera-
ture reviewing the presence of sponsorship bias, it is
common to report one overall conclusion for a paper (i.e.
overall the paper has a positive/negative/not significantly
different outcome) determined either by the reviewers,
based on the assertions of the authors or on the statistical
analysis of one primary outcome of the study [4, 7, 12]. The
method we have used, whereby we have extracted each out-
come and its result, is more achievable in the veterinary lit-
erature, as primary outcomes are often unspecified [10, 13],
but different results would potentially be obtained using a
different approach. Of note in this study is the potential for
differences between species, and potential clustering of
some types of trials, e.g. anthelmintic efficacy trials, to have
skewed the data; these limitations will be discussed in more
detail below. To date, we have found no other publications
examining the association of funding source with positive
outcome reporting in the veterinary literature with which
to compare our results. The group of trials with no funding
source stated are particularly difficult to assess in this study
as no assumptions can be made as to which of the two
other groups they would most appropriately belong to.
Within the results, they appear to be most like the non-
pharmaceutical group of trials in their characteristics, but
this in itself highlights a continuing problem of poor
reporting of clinical trials (20% of trials in this study did not
report a funding source).
Selective outcome reporting, for example not reporting,
or incompletely reporting, results for pre-specified out-
comes, or reporting outcomes that were not pre-specified,
can introduce reporting bias into a study and influence
the overall results [2, 3]. A striking feature of our data was
the high proportion of outcomes that were described only
(18.9%) or were mentioned in the materials and methods
then not reported in the results (10.3%). This could partly
be due to manuscripts not detailing clearly which of the
parameters being measured were intended to be outcomes
used to assess efficacy, leading us to misclassify the infor-
mation, highlighting again the issue of poor reporting. A
previous study reporting quality criteria and outcome data
from a sample of dog and cat trials also reported a high
percentage of outcomes with no formal statistical analysis
(31%) and a lower percentage not reported at all (3.1%)
[10]. The proportions of outcomes in these two categories
contribute to the overall high risk of reporting bias (select-
ive outcome reporting) found in this study. Research has
shown that outcomes that are not reported, or incom-
pletely reported are more likely to be statistically insignifi-
cant [14, 15]. This highlights the need for pre-specified
primary and secondary outcomes to be explicitly stated in
the methods and adhered to when reporting results. One
approach which should help to combat this problem is for
all clinical trial protocols to be registered in advance, so a
comparison can be made with the final report; this
approach is being championed by the AllTrials campaign
in human medicine. AllTrials aims to ensure that all
clinical trials are registered before they commence and
Table 4 Risk of bias for trials within different funding categories and overall
Risk of bias Pharmaceutical funding/
involvement (86 trials)
Non pharmaceutical funding
declared (19 trials)
No funding source
declared (21 trials)
All trials
(126 trials)
Sequence generation High 3 (3.5%) 0 (0%) 0 (0%) 3 (2.4%)
Low 16 (18.6%) 7 (36.8%) 8 (38.1%) 31 (24.6%)
Unclear 67 (77.9%) 12 (63.2%) 13 (61.9%) 92 (73.0%)
Allocation concealment High 5 (5.8%) 1 (5.3%) 0 (0%) 6 (4.8%)
Low 5 (5.8%) 3 (15.8%) 3 (14.3%) 11 (8.7%)
Unclear 76 (88.4%) 15 (78.9%) 18 (85.7%) 109 (86.5%)
Blinding High 5 (5.8%) 3 (15.8%) 2 (9.5%) 10 (7.9%)
Low 29 (33.7%) 7 (36.8%) 8 (38.1%) 44 (34.9%)
Unclear 52 (60.5%) 9 (47.4%) 11 (52.4%) 72 (57.1%)
Incomplete outcome reporting High 14 (16.3%) 1 (5.3%) 4 (19.0%) 19 (15.1%)
Low 36 (41.9%) 15 (78.9%) 14 (66.7%) 65 (51.6%)
Unclear 36 (41.9%) 3 (15.8%) 3 (14.3%) 42 (33.3%)
Selective outcome reporting High 18 (20.9%) 5 (26.3%) 6 (28.6%) 29 (23.0%)
Low 64 (74.4%) 11 (57.9%) 12 (57.1%) 87 (69.0%)
Unclear 4 (4.7%) 3 (15.8%) 3 (14.3%) 10 (7.9%)
Data expressed as as raw numbers and percentages of total trials
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that all are fully reported [16] (www.alltrials.net). A similar
initiative is currently underway for veterinary clinical trials
[17]; these schemes should also help to combat publica-
tion bias. Publication bias, meaning negative studies are
less likely to be published than positive ones, is a problem
that has been identified across scientific publishing gener-
ally and which can lead to over estimates of treatment ef-
fects [3, 15]. The potential impact of publication bias on
our study results would depend on who was funding any
unpublished trials.
The high proportions of ‘unclear’ risk of bias for the five
quality criteria assessed in this study indicate a significant
issue with poor reporting, a feature which has also been de-
scribed in previous quality assessments of veterinary clinical
trial literature [9, 10, 13]. This does not necessarily equate
to poor methodological trial conduct, but a lack of
complete reporting means that the methodology cannot be
adequately assessed [18, 19]. This study did not set out to
assess the impact of risk of bias on levels of positive out-
come reporting. However, it has previously been shown in
both veterinary and medical literature that incomplete or
inadequate reporting of certain quality criteria (e.g. method
of randomisation) is linked to an exaggeration of treatment
efficacy [10, 13, 20, 21].
The CONSORT reporting guideline was developed in
order to improve the reporting of RCTs, making it easier
to ascertain what was done, identify possible sources of
bias, and evaluate the reliability of a study [22, 23]. In
general, the adoption of the CONSORT checklist has
improved the reporting of RCTs in the medical litera-
ture, but there are still reporting deficits [24, 25]. In vet-
erinary medicine the REFLECT statement is also
available, which is an extension to the CONSORT
reporting guideline specifically developed for RCTs in-
volving livestock [26, 27]. Strict adherence to such
reporting guidelines [28] should have reduced all the
‘unclear’ assessments of bias made in this study and
would have allowed us to identify the funding source of
all the trials. Most importantly, this would allow more
reliable assessments of treatment efficacies to be made,
meaning more effective translation of evidence into clin-
ical practice. A recent survey assessing the awareness of
reporting guidelines amongst veterinary editors reported
that 35.1% of journal editors said reporting guidelines
were referred to in their instructions to authors [29]. An
improvement in the endorsement of reporting guidelines
by journals could help to improve the reporting quality
of the veterinary clinical trial literature as it has done for
medicine.
A significant limitation of this study is that there were a
relatively small number of trials included in the analysis,
and due to the large proportion of pharmaceutical trials in
the sample (68%), the groups for comparison were unbal-
anced and the non-pharmaceutical group small. Another,
larger study would be extremely beneficial in assessing the
presence of sponsorship bias in the veterinary clinical tri-
als literature. In particular, an exploration of potential dif-
ferences between species, or between companion animal
versus production animals, warrants further investigation
with larger sample sizes (no significant differences were
found in the current study, see Table 2). Results of this
type of study can be very dependent on the methods, in-
cluding what types of studies are included (e.g. we have
only included pharmaceutical interventions), which out-
come classifications are used, the way in which outcomes
are extracted (e.g. we did not include results for outcomes
which were not mentioned in the materials and methods)
and how funding categories are divided, meaning results
across studies could be very different. Another limitation
of this study is that the authors were not blinded to any
manuscript details during data extraction potentially
leading to biased interpretation. The lack of inclusion of
efficacy studies where multiple doses of the test treatment
were used is another significant limitation of the study.
On balance it was felt that inclusion of these could poten-
tially skew the results due to multiple entries for the trial
by including each dose, or selecting only one of the doses.
The inclusion of multiple trials within one publication
may also skew results, as the methods, and therefore as-
sessment of quality, tend to be identical for all the in-
cluded trials. As most multiple trial papers were in the
pharmaceutical category, this could potentially lead to
clustering of information. Of particular influence in this
study were RCTs assessing anthelmintic agents as these
often contained multiple similar trials with an overwhelm-
ing proportion of positive outcomes. As they fulfilled our
initial inclusion criteria they remained in our sample but
their impact on the overall results may be substantial. The
subjective assignment of a single outcome result for an
outcome which was assessed at multiple time points is
another limitation which was necessary for practicality.
Limits to the initial sample size were needed due to cost
and time constraints; a single calendar year search in
PubMed was chosen to give a representative, recent
sample of trials, rather than selecting certain journals to
search. Using PubMed also allowed us to search by publi-
cation type. Not including studies unavailable in English
was a necessary cost and time limitation but only one
paper was excluded on this basis so this is unlikely to have
affected the study outcomes.
Conclusions
This study found a positive association between pharma-
ceutical funding or involvement and increased positive
outcome reporting. Consistently poor reporting of trials,
including non-identification of funding source was
identified, which hinders the assessment and use of the
limited evidence available to the profession.
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